Showing results 1 to 5 of 5
Title | Author(s) | Issue Date | |
---|---|---|---|
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus Journal:Molecular Cancer Therapeutics | 2015 | ||
Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology | 2012 | ||
Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology | 2011 | ||
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 Proceeding/Conference:Journal of Clinical Oncology | 2011 | ||
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A) Proceeding/Conference:Journal of Clinical Oncology | 2010 |